The promise
and the potential
to effectively
treat cancer

The promise
and the potential
to effectively
treat cancer

Press releases

KAHR Announces Appointment of Jennifer Minai-Azary to its Board of Directors

More

KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein

More

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers

More

KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers

More

KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline

More

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers

More

KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy

More

KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors

More

KAHR Announces Addition of Prof. Hagop M. Kantarjian to Its Clinical Advisory Board

More

KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

More

KAHR Announces Two Key Appointments to Strengthen Leadership Team

More

KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors

More

KAHR Medical Raises $18 Million in Private Funding Round

More

KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients

More
Company Highlights

Novel Technology

Novel MIRP™ technology to generate a family of immuno-recruitment drug platforms for multiple cancers

Promising results

Robust preclinical results
Ongoing Phase I/II for solid tumors
Collaboration with ROCHE to combine with Atezolizumab

Active Pipeline

DSP-107 - Phase I/II
DSP-502 and DSP-216 - IND 2023
Multiple future candidates in R&D

Growing market

Immuno-therapeutics market
estimated at
$56.5B by 2025

Solid IP Portfolio

12 families
2 granted patents in US and ROW
10 pending patents worldwide

Strong Leadership

Seasoned management team and KOL support: technology inventor, Prof. Mark Tykocinski, Dean of the School of Medicine and Provost, Jefferson University
Get in Touch
KAHR 1 Kiryat Hadassah JBP Bldg. POB 9779, Jerusalem, 9109701, Israel T. +972.73.7969196 info@kahr-medical.com